Matt Rubin wrote an article for the National Association of Boards of Pharmacy, elaborating on the success of an international partnership between the U.S. Food and Drug Administration (FDA) and India.
Operation Broadsword, the first joint program between the FDA and India, ended in the identification of significant threats to U.S. patients with the arrival of potentially counterfeit and dangerous prescription drugs and medical devices, according to an FDA announcement.
The partnership first began with a U.S. delegation trip to New Delhi in September 2019. A few months later, the operation has prevented 500 potentially dangerous or unapproved prescription drugs from entering the U.S.
Overall, this joint program highlights the potential harms associated with illegal online drug sellers, as well as the ongoing threat that U.S. patients face from unsubstantiated retailers.